[PMC free content] [PubMed] [Google Scholar] 3. [IQR]90.0 [84.0C92.0]90.0 [86.0C93.0]<0.001Blood testsWhite bloodstream cell (K/l), median [IQR]6.10 [4.56C8.11]8.30 [6.40C11.50]<0.001eGFR (ml/min./1.73m2), median [IQR]69.8 [46.8C93.9]75.4 [49.0C97.4]0.009C reactive protein (mg/L), median [IQR]66.3 [28.0C119.7]97.1 [46.4C173.0]<0.001 d\Dimer (g/ml), median [IQR]0.94 [0.58C1.72]1.39 [0.79C2.83]<0.001TreatmentTherapeutic anticoagulation, (%)497 (32.7)329 (35.1)0.23Prophylactic anticoagulation, (%)978 (64.3)553 (59.0)0.01Steroid treatment, (%)1318 (86.6)697 (74.4)<0.001IL\6 inhibitor, (%)30 (2.0)20 (2.1)0.90Convalescent plasma, (%)698 (45.9)83 (8.9)<0.001Use of remdesivir, (%)701 (46.1)244 (26.0)<0.001In\medical center outcomesIn\medical center mortality298 (19.6)128 (13.7)<0.001Intensive care unit admission328 (21.6)186 (19.9)0.34Endotracheal intubation202 (13.3)90 (9.6)0.008Apretty kidney injuryNo severe kidney injury1186 (78.2)752 (80.4)0.45Stage 1117 (7.7)57 (6.1)Stage 248 (3.2)28 (3.0)Stage 3166 (10.9)98 (10.5)Amount of stay, median [IQR], times7.25 [4.04C13.8]6.31 [3.72C11.2]<0.001 Open up in Cinchophen another window Abbreviations: COVID\19, coronavirus disease 2019; COPD, chronic obstructive pulmonary disease; eGFR, approximated glomerular filtration price; HIV, individual immunodeficiency pathogen; IL\6, interleukin\6; IQR, interquartile range; worth
General0.680.50C0.910.01Patients without endotracheal intubation0.780.53C1.160.23Patients with endotracheal intubation0.360.17C0.770.009Patients whose air saturation??92%0.960.35C2.660.94Patients whose air saturation?CCDC122 principles of the Declaration of Helsinki. The waiver of patients’ informed consent was also approved by the institutional review boards. Notes Kuno T, So M, Miyamoto Y, Iwagami M, Takahashi M, Egorova NN. The association of COVID\19 antibody with in\hospital outcomes in COVID\19 infected patients. J Med Virol. 2021;93:6841\6844. 10.1002/jmv.27260 [PMC free article] [PubMed] [CrossRef] [Google Scholar] DATA AVAILABILITY STATEMENT Research data are not shared. REFERENCES 1. Dagan N, Barda N, Kepten E, Cinchophen et al. BNT162b2 mRNA COVID\19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412\1423. [PMC free article] [PubMed] [Google Scholar] 2. Hall VJ, Foulkes S, Charlett A, et al. SARS\CoV\2 infection rates of antibody\positive compared with antibody\negative health\care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397:1459\1469. [PMC free article] [PubMed] [Google Scholar] 3. Chandiramani.